Experience with dulaglutide in a diabetic and obese patient on incremental peritoneal dialysis

Nefrologia (Engl Ed). 2024 May-Jun;44(3):442-444. doi: 10.1016/j.nefroe.2023.10.009. Epub 2024 Jun 12.
No abstract available

Publication types

  • Letter
  • Case Reports
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetic Nephropathies / complications
  • Diabetic Nephropathies / therapy
  • Glucagon-Like Peptides* / analogs & derivatives
  • Glucagon-Like Peptides* / therapeutic use
  • Humans
  • Hypoglycemic Agents* / therapeutic use
  • Immunoglobulin Fc Fragments* / therapeutic use
  • Middle Aged
  • Obesity* / complications
  • Peritoneal Dialysis*
  • Recombinant Fusion Proteins* / therapeutic use

Substances

  • dulaglutide
  • Glucagon-Like Peptides
  • Hypoglycemic Agents
  • Immunoglobulin Fc Fragments
  • Recombinant Fusion Proteins